Expertise in
41
conditions

Dr. Andrew S. Poklepovic

Hematology Oncology | Internal Medicine
Virginia Commonwealth University Health System Authority
1300 E Marshall St, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Expertise in
41
conditions
Virginia Commonwealth University Health System Authority
1300 E Marshall St, 
Richmond, VA 

Overview

Andrew Poklepovic is a Hematologist Oncology specialist and an Internal Medicine provider practicing medicine in Richmond, Virginia.

Dr. Poklepovic is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Melanoma, Synovial Sarcoma, Angiosarcoma, Merkel Cell Carcinoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 118 peer reviewed articles and participating in 31 clinical trials. Dr. Poklepovic is currently accepting new patients.

Graduate Institution

University Of South Florida College Of Medicine

Specialties

Hematology Oncology
Internal Medicine

Licenses

Internal Medicine in VA

Hospital Affiliations

Community Memorial Hospital
Medical College Of Virginia Hospitals
Vcu Health Tappahannock Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Virginia Commonwealth University Health System Authority
1300 E Marshall St, Richmond, VA 23298

Additional Areas of Focus

Dr. Poklepovic has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Completed
Publish Date: August 25, 2026
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Enrolling_by_invitation
Publish Date: August 11, 2026
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

118 Total Publications

Case Report: Adjuvant radiation therapy for cardiac intimal sarcoma with long-term disease control.
Case Report: Adjuvant radiation therapy for cardiac intimal sarcoma with long-term disease control.
Journal: Frontiers in oncology
Published: December 20, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Sharon A. Goble
Hematology Oncology
Expertise in
34
conditions
Dr. Sharon A. Goble
Hematology Oncology
Referral may be required

Virginia Cancer Institute

1401 Johnston Willis Drive, Suite 100, 
North Chesterfield, VA 
 (7.6 miles away)
804-330-7900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharon Goble is a Hematologist Oncology provider practicing medicine in North Chesterfield, Virginia. Dr. Goble is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Triple-Negative Breast Cancer. Dr. Goble is board certified in (Internal Medicine, Medical Oncology) and American Board Of Internal Medicine. Dr. Goble is currently accepting new patients.

Expertise in
75
conditions
Dr. Attique A. Samdani
Hematology Oncology
Expertise in
75
conditions
Dr. Attique A. Samdani
Hematology Oncology
Referral may be required
6130 Harbourside Centre Loop, Ste 101, 
Midlothian, VA 
 (15.0 miles away)
804-378-0394
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Attique Samdani is a Hematologist Oncology provider practicing medicine in Midlothian, Virginia. Dr. Samdani is highly rated in 75 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast. Dr. Samdani is currently accepting new patients.

Expertise in
35
conditions
Dr. Seaborn M. Wade-Iii
Hematology Oncology
Expertise in
35
conditions
Dr. Seaborn M. Wade-Iii
Hematology Oncology
Referral may be required

Virginia Cancer Institute

7492 Right Flank Road, 
Mechanicsville, VA 
 (10.7 miles away)
804-559-2489
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Seaborn Wade-Iii is a Hematologist Oncology provider practicing medicine in Mechanicsville, Virginia. Dr. Wade-Iii is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Wade-Iii is board certified in (Internal Medicine, Medical Oncology) and American Board Of Internal Medicine. Dr. Wade-Iii is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew S. Poklepovic

How do I make an appointment with Dr. Andrew S. Poklepovic?

You can book an appointment with Dr. Andrew S. Poklepovic by calling their office at 804-828-0450. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew S. Poklepovic a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew S. Poklepovic is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew S. Poklepovic specialize in?

While Dr. Andrew S. Poklepovic is a Hematology Oncology, they have specific expertise in Melanoma, Synovial Sarcoma, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Andrew S. Poklepovic participate in research or clinical trials?

Yes. Dr. Andrew S. Poklepovic has published 118 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Andrew S. Poklepovic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew S. Poklepovic accept my insurance?

Dr. Andrew S. Poklepovic accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-828-0450 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Poklepovic's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 32 Advanced Conditions
View All 98 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile